These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

99 related items for PubMed ID: 2948442

  • 1. Improvement of hematological and general tolerance to CMF by high-dose medroxyprogesterone acetate (HD-MPA) adjuvant treatment for primary node positive breast cancer (analysis of 100 patients).
    Focan C, Baudoux A, Beauduin M, Bunescu U, Dehasque N, Dewasch L, Lobelle JP, Longeval E, Majois F, Salamon E.
    Anticancer Res; 1986; 6(5):1095-9. PubMed ID: 2948442
    [Abstract] [Full Text] [Related]

  • 2. Adjuvant high-dose medroxyprogesterone acetate for early breast cancer: 13 years update in a multicentre randomized trial.
    Focan C, Beauduin M, Salamon E, de Greve J, de Wasch G, Lobelle JP, Majois F, Tagnon A, Tytgat J, van Belle S, Vandervellen R, Vindevoghel A, Adjuvant Breast Cancer Project Belgium.
    Br J Cancer; 2001 Jul 06; 85(1):1-8. PubMed ID: 11437394
    [Abstract] [Full Text] [Related]

  • 3. Randomized trial comparing cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma.
    Cocconi G, Di Blasio B, Boni C, Bisagni G, Ceci G, Rondini E, Bella M, Leonardi F, Savoldi L, Camisa R, Bruzzi P.
    Cancer; 2002 Jul 15; 95(2):228-35. PubMed ID: 12124820
    [Abstract] [Full Text] [Related]

  • 4. Protective effect of high-dose medroxyprogesterone acetate (HD-MPA) on hematological toxicity induced by chemotherapy for advanced solid tumors: a multicentric controlled clinical trial. MPA-Hematology Italian Cooperative Group.
    Chemioterapia; 1986 Apr 15; 5(2):134-9. PubMed ID: 2871945
    [Abstract] [Full Text] [Related]

  • 5. Cyclophosphamide, methotrexate and fluorouracil (CMF) versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node-positive, premenopausal breast cancer patients: preliminary results of the TABLE-study (Takeda Adjuvant Breast cancer study with Leuprorelin Acetate).
    Schmid P, Untch M, Wallwiener D, Kossé V, Bondar G, Vassiljev L, Tarutinov V, Kienle E, Lüftner D, Possinger K, TABLE-study (Takeda Adjuvant Breast cancer study with Leuprorelin Acetate).
    Anticancer Res; 2002 Apr 15; 22(4):2325-32. PubMed ID: 12174922
    [Abstract] [Full Text] [Related]

  • 6. The potential risk of neoadjuvant chemotherapy in breast cancer patients--results from a prospective randomized trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-07).
    Taucher S, Steger GG, Jakesz R, Tausch C, Wette V, Schippinger W, Kwasny W, Reiner G, Greil R, Dubsky P, Poestlberger S, Tschmelitsch J, Samonigg H, Gnant M, Austrian Breast and Colorectal Cancer Study Group-07.
    Breast Cancer Res Treat; 2008 Nov 15; 112(2):309-16. PubMed ID: 18080748
    [Abstract] [Full Text] [Related]

  • 7. Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5.
    Levine MN, Pritchard KI, Bramwell VH, Shepherd LE, Tu D, Paul N, National Cancer Institute of Canada Clinical Trials Group.
    J Clin Oncol; 2005 Aug 01; 23(22):5166-70. PubMed ID: 16051958
    [Abstract] [Full Text] [Related]

  • 8. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in premonopausal patients with node-positive breast cancer: indirect comparison of dose and schedule in DBCG trials 77, 82, and 89.
    Ejlertsen B, Mouridsen HT, Jensen MB.
    Acta Oncol; 2008 Aug 01; 47(4):662-71. PubMed ID: 18465334
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Identifying good prognosis group of breast cancer patients with 1-3 positive axillary nodes for adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy.
    Lin YC, Chen SC, Chang HK, Hsueh S, Tsai CS, Lo YF, Hwang TL, Chen MF.
    Jpn J Clin Oncol; 2005 Sep 01; 35(9):514-9. PubMed ID: 16199422
    [Abstract] [Full Text] [Related]

  • 11. Current status of Milan adjuvant chemotherapy trials for node-positive and node-negative breast cancer.
    Bonadonna G, Valagussa P, Tancini G, Rossi A, Brambilla C, Zambetti M, Bignami P, Di Fronzo G, Silvestrini R.
    NCI Monogr; 1986 Sep 01; (1):45-9. PubMed ID: 3534590
    [Abstract] [Full Text] [Related]

  • 12. Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B.
    Weiss RB, Woolf SH, Demakos E, Holland JF, Berry DA, Falkson G, Cirrincione CT, Robbins A, Bothun S, Henderson IC, Norton L, Cancer and Leukemia Group B.
    J Clin Oncol; 2003 May 01; 21(9):1825-35. PubMed ID: 12721260
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Clinical investigation of oral high-dose medroxyprogesterone acetate (MPA) in advanced breast cancer--double-blind controlled study: Japanese Group for MPA Treatment of Breast Cancer].
    Izuo M, Tominaga T, Yoshida M, Nomura Y, Abe O, Enomoto K, Kubo K, Takatani O.
    Gan No Rinsho; 1985 May 01; 31(5):487-93. PubMed ID: 3160869
    [Abstract] [Full Text] [Related]

  • 18. Adjuvant treatment for early breast cancer: the Ludwig breast cancer studies.
    Goldhirsch A, Gelber R.
    NCI Monogr; 1986 May 01; (1):55-70. PubMed ID: 3774016
    [Abstract] [Full Text] [Related]

  • 19. A comparison of the outcomes of non-randomised chemotherapy regimens in node positive breast cancer.
    Kuru B, Camlibel M, Dinc S, Gulcelik MA, Atalay C, Alagol H.
    J Exp Clin Cancer Res; 2005 Sep 01; 24(3):363-72. PubMed ID: 16270522
    [Abstract] [Full Text] [Related]

  • 20. Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-0102.
    Hutchins LF, Green SJ, Ravdin PM, Lew D, Martino S, Abeloff M, Lyss AP, Allred C, Rivkin SE, Osborne CK.
    J Clin Oncol; 2005 Nov 20; 23(33):8313-21. PubMed ID: 16293862
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.